m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
By Huilin Huang, Hengyou Weng, Jianjun Chen. Cancer Cell, 2020
1,040 citations recorded by the source corpus.
N6-methyladenosine (m6A) RNA modification emerges in recent years as a new layer of regulatory mechanism controlling gene expression in eukaryotes. As a reversible epigenetic modification found not only in messenger RNAs (mRNAs), but also in non-coding RNAs (ncRNAs), m6A affects the fate of the modified RNA molecules and plays important roles in almost all vital bioprocesses, including cancer development. Here we review the up-to-date knowledge of the pathological roles and underlying molecular mechanism of m6A modifications (in both coding and non-coding RNAs) in cancer pathogenesis and drug response/resistance, and discuss the therapeutic potential of targeting m6A regulators for cancer therapy.
Subfields: Electrical and Electronic Engineering, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/4d2724012105160f65eca5aee37a404cf11da2e6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Electrical and Electronic Engineering
In Molecular Biology
Citations in the corpus
- Critical Roles of N6-Methyladenosine (m6A) in Cancer and Virus Infection (2020, background): “Furthermore, m6A modification has been detected in mRNAs and ncRNAs [11].”
- Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020, positive): “…been implicated in the initiation, progression, maintenance and drug resistance of various types of cancers (Deng et al., 2018b; Deng et al., 2018c; Huang et al., 2020b), the development of effective inhibitors to target m6A regulators for cancer therapy is still in its infancy (Huang et al.,…”